सेनोबामेट और लेम्बोरेक्सेंट का इंटरैक्शन

Strong or moderate CYP3A inhibitors: Avoid concomitant use.

Strong or moderate CYP3A inducers: Avoid concomitant use.

Intervention: Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors [see Dosage and Administration ( 2.2 )].

Intervention: Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inducers [see Dosage and Administration ( 2.2 )].

Risk increases with dose and use with other central nervous system (CNS) depressants.

Concomitant use with other CNS depressants or alcohol may have additive effects.

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when XCOPRI is used with other drugs with sedative properties because of potential additive effects.

CNS Depressants and Alcohol Concomitant use of XCOPRI with other CNS depressants, including alcohol, may increase the risk of neurological adverse reactions, including sedation and somnolence [see Warnings and Precautions ( 5.5 )] .